AC Immune (ACIU) Non-Current Deffered Revenue (2019 - 2026)

AC Immune (ACIU) has 5 years of Non-Current Deffered Revenue data on file, last reported at $106.8 billion in Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 113301.19% year-over-year to $106.8 billion in Q1 2026; TTM through Mar 2026 was $106.8 billion, a 113301.19% increase from a year earlier, with the FY2025 full-year figure at $101.0 billion, up 103882.67% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $106.8 billion, up from $104.7 billion in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for ACIU reached as high as $106.8 billion in Q1 2026 and fell as low as $94.2 million in Q1 2025.
• Historically, Non-Current Deffered Revenue has averaged $26.5 billion across 3 years, with a median of $100.2 million in 2025.
• Across the five-year window, Non-Current Deffered Revenue grew 5.44% in 2025 and surged 113301.19% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $97.1 million in 2024, then soared by 107765.77% to $104.7 billion in 2025, then rose by 1.98% to $106.8 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $106.8 billion in Q1 2026, $104.7 billion in Q4 2025, and $104.6 million in Q3 2025.